A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.


Updates from The Motley Fool

Latest updates on Alnylam Pharmaceuticals from Fool.com.  The Fool has written over 200 articles on Alnylam Pharmaceuticals.
Alnylam Looks Forward

An uneventful earnings release as the company anticipates an approval of its hereditary TTR amylo...



Stock Performance

View Interactive ALNY Charts
Sponsored by

Key Data Points

Primary metrics and data points about Alnylam Pharmaceuticals.
Current Price: $79.25
Prev Close: $81.26
Open: $80.95
Bid: $79.00
Ask: $79.24
Day's Range: $78.50 - $81.70
52wk Range: $78.50 - $153.98
Volume: 406,503
Avg Vol 849,251
Market Cap: $8B
P/E (ttm): -13.84
EPS (ttm): -$5.87
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Alnylam Pharmaceuticals.
CAPS Rating 4 out of 5
 
380 Outperform
36 Underperform
CAPS All Stars
 
87 Outperform
12 Underperform

How do you think Alnylam Pharmaceuticals will perform against the market?



You pick for Alnylam Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John M. Maraganore, CEO

94% Approve

Based on 42 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Alnylam Pharmaceuticals.

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers